2026 Q1 -tulosraportti
74 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,55%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenThe market for long-acting insulin is experiencing strong growth due to the increasing incidence of diabetes and a growing need for effective, long-term blood sugar control. The market is expected to grow from approx. 13.85 billion USD in 2025 to 51.42 billion USD in 2035, corresponding to an annual growth rate (CAGR) of 14.02 %. Long-acting insulin provides a stable basal insulin effect for up to 24 hours or longer and contributes to fewer blood sugar fluctuations and less need for frequent injections. North America is expected to be the largest market, while the Asia-Pacific region is expected to have the fastest growth due to increasing diabetes incidence, better access to healthcare services, and increased healthcare spending. Leading companies in the field include Novo Nordisk, Sanofi, Eli Lilly, Biocon Biologics, Boehringer Ingelheim, and Pfizer, among others. Source: Spheric Insights LLP – Long-Acting Insulin Market Research Report (market analysis and forecasts for 2025–2035).
·5 t sittenProduction capacity is a question that comes up time and again - asked Gemini and it seems that capacity is continuously increasing... see summary below.. At the same time, the pill has been launched in Saudi and UK. Germany is starting from mid-August. If Novo manages to keep up with production, H2 will be fantastic. These 3 countries outside the USA have a population of 54% of the USA, which will contribute significantly through 2026. At the same time, more EU countries will likely follow later in the autumn. GEMINI.. Even though the gigantic factory expansions take several years to complete, the increase does not happen in one big gulp. The company continuously works with what is called process optimization, which makes the supply chain more efficient month by month.These are the most important measures that provide a steady, monthly increase in the number of pills:Fjerning av flaskehalser (Debottlenecking): Engineers at the factories in Denmark and the USA trim the existing machines every week. By increasing the speed of the assembly lines, shortening the time it takes to sterilize equipment, and optimizing packaging, they manage to squeeze out a few percent more pills each month – without having to build new walls.Phased activation of production lines: When Novo Nordisk expands its facilities in Kalundborg or North Carolina, they do not wait until the entire factory is 100 % complete. They start one production line at a time (machine series) as soon as it is approved. This provides a steady supply of new pills to the market throughout the autumn.Gradual transfer of capacity: As the three newly acquired Catalent factories take over more of the syringe production in the second half of 2026, capacity is freed up at Novo's own factories almost week by week. These freed-up resources are directed straight towards the production of the active ingredient for the Wegovy-pill.
·7 t sittenPrice fluctuations in 2026/2027 are noise for a long-term investor. As long as Novo maintains its technological lead, manages to innovate before patent expiry, and revenue is converted into solid free cash flows (which can be used for share buybacks and dividends)
·10 t sittenIt will be exciting with Novo Nordisk's financial report on 05-08. And especially on Novo Nordisk's free cash flow. It is the actual earnings that Novo Nordisk can use to reduce debt or make investments or acquisitions with. But also - and - especially on share buybacks and dividend paymentsPfaaInv! I think my post disappeared. I am on my wife's computer, so I can answer you from here. You are by now a textbook example of incoherent nonsense and empty bickering. You have never written a single serious post about stocks and taxes, you have not contributed anything at all, so it's hard to take your claim seriously. I can easily document that you yourself deliver a lot of nonsense and empty talk. You read poorly, understand even worse, and then answer accordingly in the same way. I'll stop here and wish you a good evening.- ·9 t sitten · MuokattuMy family and I are sitting in our lovely summer house in Nord Vendsyssel. And laughing at the insane "stool-stickers" we have in the Folketing. We have land tax as a municipal tax. The property tax reform from either 2023/2024 has arranged the system such that municipalities, in line with increasing land valuations, correspondingly lower the land tax rate, so that the total revenue remains the same. This is equivalent to the state lowering the tax percentage every single year because we earned more money. Politicians should do the opposite, start with a gradual restructuring, where the property value tax is phased out as the land tax is strengthened. This will alleviate the geographical disparity. A continued strengthening of the land tax will create economic headroom that could be used to lower corporate tax, share income tax for Novo Nordisk and other Danish companies, as well as tax on labor and entrepreneurship. This does not happen because the system is designed: thus because landowners are many and politically active. A reform that affects them is met with organized resistance from people with a direct short-term interest in status Quo. It is rational for the individual voter, but harmful to society. These politicians have created a system that depends on whether your parents entered the property/summer house market early in the right places, where the most important economic future is not your education or your effort, but who you are born of. It is not a market. It is a succession with tax deductions. We heavily tax diligence and investment and entrepreneurship, while we let passive capital gains slide through almost without resistance, and this happens with the full blessing of the politicians.I think that debate belongs better elsewhere. Many of us follow the Novo Nordisk thread to read about the company, the stock, financial statements, products, and the latest news – not for a lengthy debate about housing taxes and tax policy. It's perfectly fine, of course, to have political opinions, but I think they fit better in a forum that deals with politics or macroeconomics. But if discussing what you believe is wrong and inadequate policy can keep your spirits up, then you sound like a person who always manages to be in a good mood. 😊 If you ever found a political party, please do write in here – then we'll know where to find your party program. Until then, I hope we can keep the focus on Novo Nordisk and the topics concerning the company and the stock. I believe most people in the thread would appreciate that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
74 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,55%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenThe market for long-acting insulin is experiencing strong growth due to the increasing incidence of diabetes and a growing need for effective, long-term blood sugar control. The market is expected to grow from approx. 13.85 billion USD in 2025 to 51.42 billion USD in 2035, corresponding to an annual growth rate (CAGR) of 14.02 %. Long-acting insulin provides a stable basal insulin effect for up to 24 hours or longer and contributes to fewer blood sugar fluctuations and less need for frequent injections. North America is expected to be the largest market, while the Asia-Pacific region is expected to have the fastest growth due to increasing diabetes incidence, better access to healthcare services, and increased healthcare spending. Leading companies in the field include Novo Nordisk, Sanofi, Eli Lilly, Biocon Biologics, Boehringer Ingelheim, and Pfizer, among others. Source: Spheric Insights LLP – Long-Acting Insulin Market Research Report (market analysis and forecasts for 2025–2035).
- ·5 t sittenProduction capacity is a question that comes up time and again - asked Gemini and it seems that capacity is continuously increasing... see summary below.. At the same time, the pill has been launched in Saudi and UK. Germany is starting from mid-August. If Novo manages to keep up with production, H2 will be fantastic. These 3 countries outside the USA have a population of 54% of the USA, which will contribute significantly through 2026. At the same time, more EU countries will likely follow later in the autumn. GEMINI.. Even though the gigantic factory expansions take several years to complete, the increase does not happen in one big gulp. The company continuously works with what is called process optimization, which makes the supply chain more efficient month by month.These are the most important measures that provide a steady, monthly increase in the number of pills:Fjerning av flaskehalser (Debottlenecking): Engineers at the factories in Denmark and the USA trim the existing machines every week. By increasing the speed of the assembly lines, shortening the time it takes to sterilize equipment, and optimizing packaging, they manage to squeeze out a few percent more pills each month – without having to build new walls.Phased activation of production lines: When Novo Nordisk expands its facilities in Kalundborg or North Carolina, they do not wait until the entire factory is 100 % complete. They start one production line at a time (machine series) as soon as it is approved. This provides a steady supply of new pills to the market throughout the autumn.Gradual transfer of capacity: As the three newly acquired Catalent factories take over more of the syringe production in the second half of 2026, capacity is freed up at Novo's own factories almost week by week. These freed-up resources are directed straight towards the production of the active ingredient for the Wegovy-pill.
- ·7 t sittenPrice fluctuations in 2026/2027 are noise for a long-term investor. As long as Novo maintains its technological lead, manages to innovate before patent expiry, and revenue is converted into solid free cash flows (which can be used for share buybacks and dividends)
- ·10 t sittenIt will be exciting with Novo Nordisk's financial report on 05-08. And especially on Novo Nordisk's free cash flow. It is the actual earnings that Novo Nordisk can use to reduce debt or make investments or acquisitions with. But also - and - especially on share buybacks and dividend paymentsPfaaInv! I think my post disappeared. I am on my wife's computer, so I can answer you from here. You are by now a textbook example of incoherent nonsense and empty bickering. You have never written a single serious post about stocks and taxes, you have not contributed anything at all, so it's hard to take your claim seriously. I can easily document that you yourself deliver a lot of nonsense and empty talk. You read poorly, understand even worse, and then answer accordingly in the same way. I'll stop here and wish you a good evening.
- ·9 t sitten · MuokattuMy family and I are sitting in our lovely summer house in Nord Vendsyssel. And laughing at the insane "stool-stickers" we have in the Folketing. We have land tax as a municipal tax. The property tax reform from either 2023/2024 has arranged the system such that municipalities, in line with increasing land valuations, correspondingly lower the land tax rate, so that the total revenue remains the same. This is equivalent to the state lowering the tax percentage every single year because we earned more money. Politicians should do the opposite, start with a gradual restructuring, where the property value tax is phased out as the land tax is strengthened. This will alleviate the geographical disparity. A continued strengthening of the land tax will create economic headroom that could be used to lower corporate tax, share income tax for Novo Nordisk and other Danish companies, as well as tax on labor and entrepreneurship. This does not happen because the system is designed: thus because landowners are many and politically active. A reform that affects them is met with organized resistance from people with a direct short-term interest in status Quo. It is rational for the individual voter, but harmful to society. These politicians have created a system that depends on whether your parents entered the property/summer house market early in the right places, where the most important economic future is not your education or your effort, but who you are born of. It is not a market. It is a succession with tax deductions. We heavily tax diligence and investment and entrepreneurship, while we let passive capital gains slide through almost without resistance, and this happens with the full blessing of the politicians.I think that debate belongs better elsewhere. Many of us follow the Novo Nordisk thread to read about the company, the stock, financial statements, products, and the latest news – not for a lengthy debate about housing taxes and tax policy. It's perfectly fine, of course, to have political opinions, but I think they fit better in a forum that deals with politics or macroeconomics. But if discussing what you believe is wrong and inadequate policy can keep your spirits up, then you sound like a person who always manages to be in a good mood. 😊 If you ever found a political party, please do write in here – then we'll know where to find your party program. Until then, I hope we can keep the focus on Novo Nordisk and the topics concerning the company and the stock. I believe most people in the thread would appreciate that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
74 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,55%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenThe market for long-acting insulin is experiencing strong growth due to the increasing incidence of diabetes and a growing need for effective, long-term blood sugar control. The market is expected to grow from approx. 13.85 billion USD in 2025 to 51.42 billion USD in 2035, corresponding to an annual growth rate (CAGR) of 14.02 %. Long-acting insulin provides a stable basal insulin effect for up to 24 hours or longer and contributes to fewer blood sugar fluctuations and less need for frequent injections. North America is expected to be the largest market, while the Asia-Pacific region is expected to have the fastest growth due to increasing diabetes incidence, better access to healthcare services, and increased healthcare spending. Leading companies in the field include Novo Nordisk, Sanofi, Eli Lilly, Biocon Biologics, Boehringer Ingelheim, and Pfizer, among others. Source: Spheric Insights LLP – Long-Acting Insulin Market Research Report (market analysis and forecasts for 2025–2035).
- ·5 t sittenProduction capacity is a question that comes up time and again - asked Gemini and it seems that capacity is continuously increasing... see summary below.. At the same time, the pill has been launched in Saudi and UK. Germany is starting from mid-August. If Novo manages to keep up with production, H2 will be fantastic. These 3 countries outside the USA have a population of 54% of the USA, which will contribute significantly through 2026. At the same time, more EU countries will likely follow later in the autumn. GEMINI.. Even though the gigantic factory expansions take several years to complete, the increase does not happen in one big gulp. The company continuously works with what is called process optimization, which makes the supply chain more efficient month by month.These are the most important measures that provide a steady, monthly increase in the number of pills:Fjerning av flaskehalser (Debottlenecking): Engineers at the factories in Denmark and the USA trim the existing machines every week. By increasing the speed of the assembly lines, shortening the time it takes to sterilize equipment, and optimizing packaging, they manage to squeeze out a few percent more pills each month – without having to build new walls.Phased activation of production lines: When Novo Nordisk expands its facilities in Kalundborg or North Carolina, they do not wait until the entire factory is 100 % complete. They start one production line at a time (machine series) as soon as it is approved. This provides a steady supply of new pills to the market throughout the autumn.Gradual transfer of capacity: As the three newly acquired Catalent factories take over more of the syringe production in the second half of 2026, capacity is freed up at Novo's own factories almost week by week. These freed-up resources are directed straight towards the production of the active ingredient for the Wegovy-pill.
- ·7 t sittenPrice fluctuations in 2026/2027 are noise for a long-term investor. As long as Novo maintains its technological lead, manages to innovate before patent expiry, and revenue is converted into solid free cash flows (which can be used for share buybacks and dividends)
- ·10 t sittenIt will be exciting with Novo Nordisk's financial report on 05-08. And especially on Novo Nordisk's free cash flow. It is the actual earnings that Novo Nordisk can use to reduce debt or make investments or acquisitions with. But also - and - especially on share buybacks and dividend paymentsPfaaInv! I think my post disappeared. I am on my wife's computer, so I can answer you from here. You are by now a textbook example of incoherent nonsense and empty bickering. You have never written a single serious post about stocks and taxes, you have not contributed anything at all, so it's hard to take your claim seriously. I can easily document that you yourself deliver a lot of nonsense and empty talk. You read poorly, understand even worse, and then answer accordingly in the same way. I'll stop here and wish you a good evening.
- ·9 t sitten · MuokattuMy family and I are sitting in our lovely summer house in Nord Vendsyssel. And laughing at the insane "stool-stickers" we have in the Folketing. We have land tax as a municipal tax. The property tax reform from either 2023/2024 has arranged the system such that municipalities, in line with increasing land valuations, correspondingly lower the land tax rate, so that the total revenue remains the same. This is equivalent to the state lowering the tax percentage every single year because we earned more money. Politicians should do the opposite, start with a gradual restructuring, where the property value tax is phased out as the land tax is strengthened. This will alleviate the geographical disparity. A continued strengthening of the land tax will create economic headroom that could be used to lower corporate tax, share income tax for Novo Nordisk and other Danish companies, as well as tax on labor and entrepreneurship. This does not happen because the system is designed: thus because landowners are many and politically active. A reform that affects them is met with organized resistance from people with a direct short-term interest in status Quo. It is rational for the individual voter, but harmful to society. These politicians have created a system that depends on whether your parents entered the property/summer house market early in the right places, where the most important economic future is not your education or your effort, but who you are born of. It is not a market. It is a succession with tax deductions. We heavily tax diligence and investment and entrepreneurship, while we let passive capital gains slide through almost without resistance, and this happens with the full blessing of the politicians.I think that debate belongs better elsewhere. Many of us follow the Novo Nordisk thread to read about the company, the stock, financial statements, products, and the latest news – not for a lengthy debate about housing taxes and tax policy. It's perfectly fine, of course, to have political opinions, but I think they fit better in a forum that deals with politics or macroeconomics. But if discussing what you believe is wrong and inadequate policy can keep your spirits up, then you sound like a person who always manages to be in a good mood. 😊 If you ever found a political party, please do write in here – then we'll know where to find your party program. Until then, I hope we can keep the focus on Novo Nordisk and the topics concerning the company and the stock. I believe most people in the thread would appreciate that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt